Latest New England Journal Stories
Findings from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, have revealed that adding the medication known as spironolactone (Aldactone) to existing therapy did not significantly reduce the composite time to either death from cardiovascular causes, surviving a cardiac arrest, or hospitaliization to manage heart failure in patients with heart failure and a preserved ejection fraction in a study funded by the National Heart, Lung and...
Kanti Rai, MD, and Jacqueline Barrientos, MD, comment on study of new leukemia therapy. Lake Success, NY (PRWEB) March 20, 2014 Two
Use of a twice-daily pill could turn a deadly blood cancer into a highly treatable disease.
A major trial aiming to cut the rate of tuberculosis (TB) among South Africa's gold miners did not reduce the number of cases or deaths from the disease.
The U.S. should prepare for more outbreaks of illness and possible deaths from designer drugs including synthetic marijuana.
Adverse Events for Heart Attack, Heart Failure Decline; Improvements Lag for Pneumonia and Surgical Patients Wethersfield, CN (PRWEB) January 23, 2014
A team of scientists from the University of Leicester has demonstrated a novel treatment for Hairy Cell Leukaemia (HCL), a rare type of blood cancer, using a drug administered to combat skin cancer.
An endotracheal extubation training video produced by Rafael Ortega, MD, the vice-chair of academic affairs for the department of anesthesiology at Boston Medical Center (BMC) and professor of anesthesiology at Boston University School of Medicine (BUSM), and his colleagues is featured in this week's New England Journal of Medicine.
Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective.
Being overweight or obese does not lead to improved survival among patients with type 2 diabetes.
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.